Pancreatic ductal adenocarcinoma (PDAC) is a highly devastating disease with poor
prognosis and rising incidence. Late detection and a particularly aggressive biology are the …

The current preclinical and clinical findings demonstrate that, in addition to the conventional
clinical and pathological indicators that have a prognostic value in radiation oncology, the …

Both embryonic and adult stem cells are endowed with a superior capacity to prevent the
accumulation of genetic lesions, repair them, or avoid their propagation to daughter cells …

The cell cycle checkpoint proteins ataxia-telangiectasia-mutated-and-Rad3-related kinase
(ATR) and its major downstream effector checkpoint kinase 1 (CHK1) prevent the entry of …

Targeted radionuclide therapy (TRT) is a branch of cancer medicine concerned with the use
of radioisotopes, radiolabelled molecules, nanoparticles, or microparticles that either …

Metastases expressing tumor-specific receptors can be targeted and treated by binding of
radiolabeled peptides (peptide receptor radionuclide therapy or PRRT). For example …

DNA inevitably undergoes a high number of damages throughout the cell cycle. To preserve
the integrity of the genome, cells have developed a complex enzymatic machinery aimed at …

Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal solid
malignancies with very few therapeutic options to treat advanced or metastatic disease. The …

Background Breast cancer remains as one of the most lethal types of cancer in women.
Among various subtypes, triple-negative breast cancer (TNBC) is the most aggressive and …

Background Pancreatic cancer has a five-year survival rate of~ 8%, with characteristic
molecular heterogeneity and restricted treatment options. Targeting metabolism has …